Gene Patents and Other Genomic Inventions: Hearing Before the Subcommittee on Courts and Intellectual Property of the Committee on the Judiciary, House of Representatives, One Hundred Sixth Congress, Second Session, July 13, 2000U.S. Government Printing Office, 2000 - 104 lappuses |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
acid of claim alpha subunit amino acid base pairs Bayh-Dole Act BERMAN beta subunit displays binding biological biotechnology cDNA cell COBLE companies comprising the variant diagnostic discovery disease displays a dominant dominant negative effect drug endogenous IGF-I receptor fibroblasts gene patents Genentech genetic genomic information genomic inventions human genome human genome project IGF-I receptor comprising IGF-I receptor subunit Incyte's industry INFORMATION FOR SEQ Insulin-like Growth Factor intellectual property issues KGF-I kidney cancer ligand modified IGF-I modified polynucleic acid nucleic acid nucleotide patent application patent law patent protection patent system pharmaceutical polynucleic acid encoding present invention protein recombinant polynucleic acid research tools residue SEQ ID transfectants tyrosine kinase tyrosine kinase activity USPTO utility variant beta subunit variant IGF-I receptor Varmus vector wherein the IGF-I
Populāri fragmenti
9. lappuse - Here, by contrast, the patentee has produced a new bacterium with markedly different characteristics from any found in nature and one having the potential for significant utility. His discovery is not nature's handiwork, but his own; accordingly it is patentable subject matter under § 101.
51. lappuse - ... the specification shall contain a written description of the invention (description requirement); b. the manner and process of making and using it in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the invention (enablement requirement); and c.
10. lappuse - ... real world" context of use in identifying potential candidates for preventive measures or further monitoring. On the other hand, the following are examples of situations that require or constitute carrying out further research to identify or reasonably confirm a "real world...
83. lappuse - Its 75,000 members include board certified pathologists, other physicians, clinical scientists, and certified technologists and technicians. These professionals recognize the Society as the principal source of continuing education in pathology and as the leading organization for the certification of laboratory personnel.
8. lappuse - Congress shall have power to promote the progress of science and useful arts by securing for limited times to inventors the exclusive right to their respective discoveries.
8. lappuse - To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries.
6. lappuse - The Committee Reports accompanying the 1952 Act inform us that Congress intended statutory subject matter to "include anything under the sun that is made by man.
8. lappuse - Century Competitiveness, Committee on Education and the Workforce US House of Representatives "Welfare Reform: Success in Moving Toward Work" October 16, 2001 Mr. Chairman and Members of the Subcommittee: Thank you very much for inviting me to testify today.
9. lappuse - In the language of the statute, any person who "invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent," subject to the conditions and requirements of the law.
9. lappuse - manifestations of ... nature, free to all men and reserved exclusively to none." Funk, supra, at 130. Judged in this light, respondent's micro-organism plainly qualifies as patentable subject matter. His claim is not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter — a product of human ingenuity "having a distinctive name, character [and] use.